Bevacizumab biosimilar - Qilu Pharmaceutical

Drug Profile

Bevacizumab biosimilar - Qilu Pharmaceutical

Alternative Names: QL 1101

Latest Information Update: 29 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Qilu Pharmaceutical
  • Developer Qilu Pharmaceutical; Tianjin Medical University Cancer Institute and Hospital
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action Angiogenesis inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Non-small cell lung cancer

Most Recent Events

  • 25 May 2017 Phase-III clinical trials in Non-small cell lung cancer (Late-stage disease, First-line therapy) in China (IV) (NCT03169335)
  • 01 Mar 2017 Phase-III clinical trials in Non-small cell lung cancer (Second-line therapy or greater, In adults, In the elderly, Late-stage disease) in China (IV) (NCT03195569)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top